The diagnosis and treatment of pulmonary embolism

A metaphor for medicine in the evidence-based medicine era

Vinay Prasad, Jason Rho, Adam Cifu

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: The history of pulmonary embolism (PE) provides a fascinating portrait of a well-established diagnosis and standard of care treatment moving into the age of evidence-based medicine. Methods: We examined the history of PE and the practice of treating PE with anticoagulation. Results: Pulmonary embolism is a diagnostic category whose definition and treatment have both changed in the past century. Initially, PE was recognizable only when massive, with the signs and symptoms of right heart failure. Anticoagulants were established as the cornerstone of PE management with a single randomized controlled trial of 35 patients in 1960 and based on commonsense pathophysiologic reasoning. Since then, the diagnostic category of PE has been broadened, and the advent of computed tomography pulmonary angiography has yielded nearly a doubling of the incidence of the disease, without a concordant decrease in mortality. Although anti-coagulation remains the cornerstone of management, open questions remain: what end points are altered by anti-coagulation? What is the number needed to treat? Conclusions: Trials of newer anticoagulants and longer durations of anticoagulation have not yielded real improvements over heparin, inviting doubts regarding its efficacy. Thus, PE is the quintessential diagnosis of medicine not because it represents our greatest success, but because it captures all the complexity of medicine in the evidence-based era. It may serve as a metaphor for many other conditions in medicine, including coronary artery disease. New trials in the field continue to test trivialities, whereas fundamental questions are unanswered.

Original languageEnglish (US)
Pages (from-to)955-958
Number of pages4
JournalArchives of Internal Medicine
Volume172
Issue number12
DOIs
StatePublished - Jun 25 2012
Externally publishedYes

Fingerprint

Metaphor
Evidence-Based Medicine
Pulmonary Embolism
Medicine
Therapeutics
Anticoagulants
History
Numbers Needed To Treat
Standard of Care
Signs and Symptoms
Heparin
Coronary Artery Disease
Randomized Controlled Trials
Heart Failure
Lung
Mortality
Incidence

ASJC Scopus subject areas

  • Internal Medicine

Cite this

The diagnosis and treatment of pulmonary embolism : A metaphor for medicine in the evidence-based medicine era. / Prasad, Vinay; Rho, Jason; Cifu, Adam.

In: Archives of Internal Medicine, Vol. 172, No. 12, 25.06.2012, p. 955-958.

Research output: Contribution to journalArticle

@article{0596dcf7f7694d12bd868b2681e32ca0,
title = "The diagnosis and treatment of pulmonary embolism: A metaphor for medicine in the evidence-based medicine era",
abstract = "Background: The history of pulmonary embolism (PE) provides a fascinating portrait of a well-established diagnosis and standard of care treatment moving into the age of evidence-based medicine. Methods: We examined the history of PE and the practice of treating PE with anticoagulation. Results: Pulmonary embolism is a diagnostic category whose definition and treatment have both changed in the past century. Initially, PE was recognizable only when massive, with the signs and symptoms of right heart failure. Anticoagulants were established as the cornerstone of PE management with a single randomized controlled trial of 35 patients in 1960 and based on commonsense pathophysiologic reasoning. Since then, the diagnostic category of PE has been broadened, and the advent of computed tomography pulmonary angiography has yielded nearly a doubling of the incidence of the disease, without a concordant decrease in mortality. Although anti-coagulation remains the cornerstone of management, open questions remain: what end points are altered by anti-coagulation? What is the number needed to treat? Conclusions: Trials of newer anticoagulants and longer durations of anticoagulation have not yielded real improvements over heparin, inviting doubts regarding its efficacy. Thus, PE is the quintessential diagnosis of medicine not because it represents our greatest success, but because it captures all the complexity of medicine in the evidence-based era. It may serve as a metaphor for many other conditions in medicine, including coronary artery disease. New trials in the field continue to test trivialities, whereas fundamental questions are unanswered.",
author = "Vinay Prasad and Jason Rho and Adam Cifu",
year = "2012",
month = "6",
day = "25",
doi = "10.1001/archinternmed.2012.195",
language = "English (US)",
volume = "172",
pages = "955--958",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - The diagnosis and treatment of pulmonary embolism

T2 - A metaphor for medicine in the evidence-based medicine era

AU - Prasad, Vinay

AU - Rho, Jason

AU - Cifu, Adam

PY - 2012/6/25

Y1 - 2012/6/25

N2 - Background: The history of pulmonary embolism (PE) provides a fascinating portrait of a well-established diagnosis and standard of care treatment moving into the age of evidence-based medicine. Methods: We examined the history of PE and the practice of treating PE with anticoagulation. Results: Pulmonary embolism is a diagnostic category whose definition and treatment have both changed in the past century. Initially, PE was recognizable only when massive, with the signs and symptoms of right heart failure. Anticoagulants were established as the cornerstone of PE management with a single randomized controlled trial of 35 patients in 1960 and based on commonsense pathophysiologic reasoning. Since then, the diagnostic category of PE has been broadened, and the advent of computed tomography pulmonary angiography has yielded nearly a doubling of the incidence of the disease, without a concordant decrease in mortality. Although anti-coagulation remains the cornerstone of management, open questions remain: what end points are altered by anti-coagulation? What is the number needed to treat? Conclusions: Trials of newer anticoagulants and longer durations of anticoagulation have not yielded real improvements over heparin, inviting doubts regarding its efficacy. Thus, PE is the quintessential diagnosis of medicine not because it represents our greatest success, but because it captures all the complexity of medicine in the evidence-based era. It may serve as a metaphor for many other conditions in medicine, including coronary artery disease. New trials in the field continue to test trivialities, whereas fundamental questions are unanswered.

AB - Background: The history of pulmonary embolism (PE) provides a fascinating portrait of a well-established diagnosis and standard of care treatment moving into the age of evidence-based medicine. Methods: We examined the history of PE and the practice of treating PE with anticoagulation. Results: Pulmonary embolism is a diagnostic category whose definition and treatment have both changed in the past century. Initially, PE was recognizable only when massive, with the signs and symptoms of right heart failure. Anticoagulants were established as the cornerstone of PE management with a single randomized controlled trial of 35 patients in 1960 and based on commonsense pathophysiologic reasoning. Since then, the diagnostic category of PE has been broadened, and the advent of computed tomography pulmonary angiography has yielded nearly a doubling of the incidence of the disease, without a concordant decrease in mortality. Although anti-coagulation remains the cornerstone of management, open questions remain: what end points are altered by anti-coagulation? What is the number needed to treat? Conclusions: Trials of newer anticoagulants and longer durations of anticoagulation have not yielded real improvements over heparin, inviting doubts regarding its efficacy. Thus, PE is the quintessential diagnosis of medicine not because it represents our greatest success, but because it captures all the complexity of medicine in the evidence-based era. It may serve as a metaphor for many other conditions in medicine, including coronary artery disease. New trials in the field continue to test trivialities, whereas fundamental questions are unanswered.

UR - http://www.scopus.com/inward/record.url?scp=84862977655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862977655&partnerID=8YFLogxK

U2 - 10.1001/archinternmed.2012.195

DO - 10.1001/archinternmed.2012.195

M3 - Article

VL - 172

SP - 955

EP - 958

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 12

ER -